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Mass spectrometry (MS)-based proteomics has developed tremendously in recent years and 
was the leading technology for many novel methods to study protein chemistry. Contrary to 
classical approaches based on Western blot, MS-based approaches are mostly unbiased. In 
addition to protein expression levels, today several protein chemical properties can be 
examined by MS-based proteomics making it unique in comparison to transcriptomics 
approaches. These properties include post-translational modifications (PTMs), protein 
localization, synthesis/degradation, and lastly protein thermal stability, adding novel 
dimensions or facets to characterize the proteome. However, these facets are difficult to 
combine as they are mainly orthogonal and are therefore often analyzed separately. This 
thesis presents a simplified and higher throughput version of current protein stability analyses 
and showcases the advantages of combined/merged analysis of proteomics facets including 
our new method, as well as expression and redox proteomics to study anticancer treatments 
and cellular dynamics.  
In paper I, we studied the dynamics of cancer cells in vitro with and without anticancer 
treatment over the course of 48 h by monitoring protein expression every 6 h. We discovered 
that naturally occurring proteome variations are on par with anticancer treatment killing 50% 
of the cells after 48 h. Then, we acquired a deep proteomics dataset of untreated HCT116 and 
A375 cell lines. Surprisingly, we observed downregulation of proteins involved in cell 
division and upregulation of proteins involved in metabolism as early as 12 h after treatment, 
suggesting that growth inhibition happens earlier than usually assumed and even at low cell 
confluence.  
In paper II we developed the proteome integral solubility alteration (PISA) assay that 
increases the throughput of pre-existing drug target deconvolution methods based on protein 
stability/solubility measurements and reduces the analysis time and cost as well as sample 
requirements. We provided theoretical calculations showing that the integral of the curve 
correlates well with melting temperature estimations in Thermal Proteome Profiling (TPP) 
and tested our assumptions with publicly available TPP datasets. Then we performed a proof 
of principle experiment using the well-studied methotrexate (MTX) and 5-fluorouracile (5-
FU) as test drugs highlighting the targets as outliers with our method. Furthermore, we 
demonstrated that PISA assay can also be used for concentration series analysis as in 2D-
TPP. Finally, we showcased the higher throughput of PISA compared to TPP by 
simultaneously analyzing nine drugs in one multiplexed analysis. 
In paper III we used a combination of chemical proteomics approaches to study the target 
and mechanism of action (MOA) of Auranofin (AF) (Ridaura®). Functional Identification of 
Target by Expression Proteomics (FITExP), TPP, and redox proteomics combined 
highlighted that thioredoxin reductase 1 (TXNRD1) is indeed a top target hit of AF, and that 
the main MOA of the drug is through disruption of the redox balance in the cell. Finally, we 
showed that protein thermal shifts can be associated with altered cysteine oxidation levels in 
proteins, suggesting that TPP is suitable to study disulfide bond formation/reduction and map 
some cysteines to the active sites of sulfiredoxin 1 (SRXN1) and peroxiredoxin 5 (PRDX5) 
as examples. Overall, our study demonstrates that using only one of the proteomics methods 
is not sufficient to accurately pinpoint drug target and MOA, but a combination of multiple 
complementary methods should be used instead.  
Following the success of our strategy in paper III, we decided to utilize the same strategy in 
paper IV using PISA developed in paper II instead of TPP, to study two novel inhibitors of 
TXNRD1, namely TRi-1 and TRi-2. For these studies, we used the mouse cancer cell lines 
B16-F10 and Lewis lung carcinoma (LLC) to provide a comprehensive analysis of the 
therapeutic effects of the inhibitors. Since we showed that Txnrd1 (the mouse version of the 
human TXNRD1 protein) is a main target of AF, we decided to use it as our reference point 
to evaluate the specificity of the two new compounds. AF had a broader effect on the 
proteome than TRi-1 and TRi-2 and had more target hits in PISA analyses. This suggested 
that AF has lower specificity than TRi-1 and TRi-2. TRi-1 was the most specific Txnrd1 
inhibitor with a better target ranking in FITExP and the least target hits in PISA followed by 
TRi-2 and AF. Thus, we showed that TRi-1 and TRi-2 are indeed more specific inhibitors of 
Txnrd1. In addition to these findings, we also highlighted that only AF triggers a high nuclear 
factor erythroid 2-related factor 2 (Nrf2) antioxidant response, suggesting that this response is 
not necessarily Txnrd1-dependent. Finally, we detected selenocysteine-specific elongation 
factor (Eefsec), mini-chromosome maintenance complex-binding protein (Mcmbp), glycogen 
synthase kinase-3 (Gsk3) a and b, as target hits of AF, which would explain at least partially 
three different effects of AF treatment. Collectively, our data represents a resource for redox 
biologists interested in Txnrd1 inhibition. Our approach provides a framework for target 
deconvolution using proteomics approaches.  
Finally, in paper V we studied the dynamics of the proteome in transition between various 
cell types. We reprogrammed human foreskin fibroblasts (hFF) into induced pluripotent stem 
cells (iPSCs), which we differentiated through embryoid bodies (EBs) formation. We 
examined protein expression and stability after each cell type transition using PISA-Express, 
a new version of the PISA assay developed in paper II. We merged the readout from protein 
expression and thermal stability in one analysis using Sankey diagrams to detect changes in 
protein properties during proteome transitions resulting in the ProteoTracker web interface 
(http://www.proteotracker.genexplain.com/). Using this innovative analysis, we discovered 
that ribosomes are less stable in pluripotent stem cells (PSCs) compared to differentiated cells 
and that this difference stems from the deficiency of one ribosome maturation factor, 
Shwachman-Bodian-Diamond syndrome protein (SBDS). Knock-down (KD) of SBDS 
slowed down translation and increased expression of the master pluripotency markers 
homeobox protein NANOG (NANOG), and octamer-binding transcription factor 4 (OCT4). 
Collectively, we developed a new method for simultaneous analysis of protein thermal 
stability and expression, a new analysis and visualization tool, and provided evidence that 
control of translation through ribosome biogenesis is a natural mechanism used by PSCs to 
maintain the pluripotency state. 
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1.1 DECONVOLUTION STRATEGIES IN DRUG DEVELOPMENT 
AND STEM CELL RESEARCH 
Only 7% of the compounds entering phase I clinical trials end up being approved for 
therapy (Dowden & Munro, 2019). Seventy-nine percent of these drugs failed for efficacy 
and safety reasons during the 2016-2018 period and these numbers were similar in 
previous years (Arrowsmith & Miller, 2013; Harrison, 2016), highlighting the gap 
between preclinical studies in cell lines and animal models and human clinical trials. Part 
of the problem lies in overinterpretation of the results, bias, and inaccurate 
characterization of the compounds’ target landscape, and mechanism of action (MOA) 
(Colquhoun, 2014; Halsey et al., 2015). Target deconvolution is present in every phase 
of drug development in both target-based and phenotypic drug discovery (Noberini & 
Bonaldi, 2019) (Figure 1), but even for drugs used in the clinic, off-targets are still 
discovered today due to the development of new methods (Klaeger et al., 2016; M. M. 
F. Savitski et al., 2014). However, not all discovered off-targets have a negative impact 
since they can also lead to repurposing of the drug for treating other diseases or help in 
compound optimization. Consequently, the pharmaceutical industry would benefit from the 
development of better preclinical methods for accurate characterization of the 
target landscape and MOA of lead compounds. 
Figure 1. Target deconvolution in 
drug discovery. Scheme of the 
different stages of drug discovery. 
Target deconvolution is involved 
throughout drug discovery in 
phenotypic drug discovery while it is 
involved in the late stages for target-
based drug discovery. HTS: High-
throughput screen. Redrawn by 
permission from Springer Nature 
Customer Service Centre GmbH: 
Springer Nature, Nature Structural & 
Molecular Biology, Epigenetic drug 
target deconvolution by mass 
spectrometry–based technologies, 
(Noberini & Bonaldi, 2019). 
Conversely, discovering new mechanistic targets that could be affected by chemicals or other 
molecules to achieve the desired effect in diseases or cell biology is also valuable. For 
example, in the stem cell field and regenerative medicine, the ability to maintain and expand 
specific types of stem cells and/or direct their differentiation into specific cell types is of 
utmost importance to accelerate the development and approval of stem cells-based therapies 
(Poulos, 2018). Cocktails of small molecule inhibitors and growth factors are used to 
differentiate stem cells in various cell types and tissues such as airway epithelial cells (Wong 
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et al., 2012), megakaryocytes (Nakamura et al., 2014), intestinal tissue (Spence et al., 2011), 
cardiomyocytes (Lian et al., 2012), nephron organoids (Morizane et al., 2015), neurons (Lu et 
al., 2016; Nolbrant et al., 2017), pancreatic β cells (Pagliuca et al., 2014) and retina cells 
(Osakada et al., 2009). This is also relevant in precision medicine and targeted therapies 
where treatments are adapted based on the patients’ genetics and where the knowledge of 
key mechanistic proteins can help choosing optimal treatments (Collins & Varmus, 
2015; Lamberti et al., 2018; Srivastava et al., 2018). Understanding the underlying 
mechanisms of diseases and cell type transitions is crucial for developing more effective 
drug and cell-based therapies. Consequently, there is a need for more efficient methods to 
deconvolute drug targets and cellular mechanisms for the development of novel therapies. 
1.2 CHEMICAL PROTEOMICS IN STUDYING TARGETS AND 
MECHANISMS OF ACTION OF SMALL MOLECULE INHIBITORS 
Standard approaches of chemical proteomics employ affinity pull-downs or chromatography 
methods using drugs or probes that bind to specific enzymes, usually coupled to SDS-PAGE 
or mass spectrometry analysis (Jeffery & Bogyo, 2003). However, mass spectrometry-based 
proteomics methods have become increasingly powerful in recent years by enabling the 
possibility to monitor thousands of proteins simultaneously (Hornburg et al., 2014; 
Pirmoradian et al., 2013; Wei et al., 2016; Zhou et al., 2013). In addition, mass spectrometry 
offers unique possibilities to study in an unbiased manner various aspects of protein 
chemistry, such as post-translational modifications (PTM), small molecules-protein 
interactions and protein-protein interactions (PPI) as well as protein structure and thermal 
stability (J. X. Huang et al., 2019; Lomenick et al., 2009; Molina et al., 2013; Saei et al., 
2021; M. M. F. Savitski et al., 2014; Schopper et al., 2017). Thus, the chemical proteomics 
field expanded to the broader use of mass spectrometry-based approaches in general. Now, 
chemical proteomics is defined as a multidisciplinary field that aims to study how 
small-molecule compounds bind to proteins and modulate their function (Tao & Zhang, 
2019), primarily focused on drug target deconvolution and target discovery. 
1.3 ANALYTICAL DIMENSIONS AND METHODS IN MASS 
SPECTROMETRY-BASED PROTEOMICS AND CHEMICAL 
PROTEOMICS 
1.3.1 Chemical probe-based methods 
Initially, chemical proteomics encompassed the use of specifically designed probes to study 
enzyme-substrate or drug-proteins interactions. Activity-based and affinity-based were the 
main types of probes. The functions of many proteins remain unknown, and the discovery of 
new enzymes is crucial for both fundamental biology and drug discovery. The development 
of Activity-Based Protein Profiling (ABPP) (Yongsheng Liu et al., 1999) was a major step 
forward to address the issue. In ABPP, specific probes are designed to target a particular 
feature of a family of enzymes (Figure 2). New protein functions can be assigned using this 
approach. The probes consist of a reactive group that binds covalently to a specific domain of 
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an enzyme class (in most cases to the catalytic domain). It is connected by a linker to a tag 
providing an identifier for proteins that are bound to the probe, which is also used for pulling 
down the proteins followed by identification using liquid chromatography coupled to tandem 
mass spectrometry (LC-MS/MS). Probes for numerous enzyme types have been designed 
over the years and have been very successful in assigning new enzymatic functions to 
proteins (Barglow & Cravatt, 2007; Zweerink et al., 2017). Such probes have also facilitated 
drug discovery via the establishment of a high-throughput platform (Bachovchin et al., 2009). 
For instance, using this platform, Bachovchin et al. discovered new inhibitors of GSTO1 and 
RRBP9 (Bachovchin et al., 2009).  
While ABPP is mainly focused on enzymatic activity, the second type of probes used in 
chemical proteomics is affinity purification-based chemical probes that focus on 
target deconvolution. This approach is called Compound-Centric Chemical Proteomics 
(CCCP) (Figure 2). In this approach, the reactive group is replaced by a drug that binds to a 
specific or to multiple protein targets (Chan et al., 2004; Shi et al., 2012). Usually, the 
compound is immobilized on beads (or on a resin). The beads are incubated with a cell 
lysate or a protein mixture, washed extensively and proteins bound to the drug are 
subjected to proteolytic digestion to release peptides that are analysed and identified 
by LC-MS/MS. One of the disadvantages of this method is that proteins can 
potentially strongly bind directly to the beads without interaction with the drug and 
remain even after extensive washing. 
Additionally, other proteins that are interacting 
with the real target of the drug can be pulled 
down along thus creating false positive 
identifications (J. Wang et al., 2016). One more 
disadvantage of the method is that the design of 
the probe can alter the activity of the drug and 
binding affinity to its target. Therefore, the 
activity of the probe needs to be confirmed by 
comparison with the unmodified drug 
before starting experiments. Some compounds 
do not even allow for the addition of a 
linker. Finally, in affinity purification, 
the target proteins are not covalently bound, 
making the washing steps and accurate 
pull down a challenging task.  
 Figure 2. Probe-based chemical proteomics methods. 
Schematic view of typical workflows in Activity-Based 
Protein Profiling (ABPP) and Compound-Centric 
Chemical Proteomics (CCCP). Reprinted by permission 
from Springer Nature Customer Service Centre GmbH: 
Springer Nature, Nature Chemical Biology, Target 
profiling of small molecules by chemical proteomics, 
(Rix & Superti-Furga, 2009). 
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An example of an affinity purification strategy is the use of kinobeads (Bantscheff et al., 
2007). They consist of more than a hundred kinase inhibitors and ATP-mimetics immobilized 
on beads. These drugs/probes bind to the ATP binding pocket of kinases and purine-binding 
proteins and can capture a substantial fraction of these proteins present in a cell lysate. 
Contrary to other affinity-based approaches, kinobeads do not aim to determine the targets of 
the drugs bound to the beads. Instead, a tested “free” kinase inhibitor is also added to the cell 
lysate and will compete with the kinobeads to bind to its targets. Then, the targets of the 
tested drug are deconvoluted by measuring the concentration of proteins bound to the 
kinobeads. It is also possible to determine affinity curves using a concentration range of the 
tested drug. The advantage of this approach is that there is no need to chemically modify the 
compound of interest. Kinobeads have been successfully used to characterize kinase 
inhibitors and particularly in a study involving 243 kinase inhibitors used in clinics (Klaeger 
et al., 2017). Kinobeads have been also employed to confirm a common off-target of kinase 
inhibitors, ferrochelatase (FECH) (Klaeger et al., 2016).  
The main drawback of ABPP and CCCP lies in the design of the probes or the 
drug immobilization, which can be labour-intensive. The design of the probes is also 
important to avoid false positive or false negative results. The advantages of these 
approaches are that they are unbiased and can be coupled with stable isotope or isobaric 
labelling to increase their accuracy and throughput (Bantscheff et al., 2007; Ong et al., 
2009).  
1.3.2 Shotgun analysis in chemical proteomics 
Another classical workflow in chemical proteomics is a shotgun analysis of cell lines 
or animal and human tissues after treatment with a drug, to monitor the effect on the 
cellular proteome (Fatima et al., 2009; Voruganti et al., 2013). The widely accepted 
hypothesis behind such experiments is that the effect of the chemical is reflected in the 
variation of protein concentration within the MOA of the drug and feedback loops 
(Chakrabarty et al., 2012; Wan et al., 2007). The most common method is based on the 
bottom-up approach where proteins from cells or tissue lysates are digested, and the 
resulting peptide mixture is analysed by mass spectrometry (McDonald & Yates, 2003; 
Swanson & Washburn, 2005; Wu & MacCoss, 2002) (Figure 3). Both label-free 
and labelling methods exist for protein quantification, with the latter being more 
commonly used. The main reason is that label-free techniques are still limited by the 
analysis throughput and analysis depth due to the dynamic range of protein concentrations 
in cells. 
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Figure 3. Shotgun (bottom-up) chemical proteomics workflow. (a) Cells are treated with a drug, then lysed to 
extract the proteins. Proteins are then reduced with dithiothreitol (DTT), alkylated with iodoacetamide (IAA), 
and digested into peptides with trypsin and/or lysyl endopeptidase (lysC). (b) The peptide mixture is analysed by 
LC-MS/MS for each sample independently. (c) Precursors are selected in a full scan (MS) and fragmented for 
MS/MS. (d) The MS/MS spectra are matched to a peptide database to identify the protein of origin. 
Quantification of a protein is performed using the intensity of all its identified peptides corresponding to their 
signal in MS. (e) Differences in relative abundance between conditions A (drug-treated) and B highlights 
potential targets of the treatment.  
Several labelling technologies have been developed over the years and currently, SILAC 
(Ong et al., 2002), iTRAQ (Ross et al., 2004), and TMT (Thompson et al., 2003) are the most 
widely used labelling approaches allowing for multiplexing of up to 16 samples (J. Li et al., 
2020; Thompson et al., 2019), greatly increasing the speed of the analysis. Moreover, since 
samples are prepared simultaneously, they can be fractionated off-line prior to LC-MS/MS. 
One of the limitations of reversed-phase liquid chromatography coupled to MS/MS is that 
mass spectrometers are not fast enough to process the enormous number of peptides that are 
eluted simultaneously and only the most abundant peptides are usually identified. This can 
hamper the detection of low abundant proteins such as those involved in signal transduction. 
One way to solve this issue is to pre-fractionate the samples with an orthogonal dimension to 
low-pH reversed-phase chromatography. Consequently, samples are now routinely 
fractionated using isoelectric focusing (Branca et al., 2014; Pirmoradian et al., 2014) or the 
semi-orthogonal high-pH reversed-phase liquid chromatography (H. Wang et al., 2015; F. 
Yang et al., 2012) reaching high proteome coverage in a reasonable analysis time which 
would be difficult to achieve using contemporary label-free technologies.  
1.3.3 Advanced approaches based upon protein expression analyses 
FITExP (Chernobrovkin et al., 2015; Gaetani & Zubarev, 2019; R. F. S. S. Lee et al., 2017a; 
Saei et al., 2019) employs shotgun proteomics for the identification of drug MOA, adding a 
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specificity component to the conventional protein concentration measurements. In FITExP, 
several cell lines are treated with multiple drugs targeting various proteins (Figure 4). Then, 
the proteome signature of each compound is captured by LC-MS/MS analysis and is 
contrasted against the signatures of all the other compounds in each cell line to highlight 
specific features and eliminate cell type-specific response and default cells detoxification 
response to foreign chemicals. The authors successfully showed that MTX known target, 
dihydrofolate reductase (DHFR), was identified as the top target candidate. The authors also 
identified TYMS, the target of 5-FU, and demonstrated that it affects ribosome biogenesis as 
a new mechanistic insight. Later, FITExP was used to study metallodrugs (R. F. S. S. Lee et 
al., 2017b) and evaluate the cytotoxicity and pro-inflammatory effects of nanoparticles 
on monocytes (Tarasova et al., 2017). We recently modified FITExP by including 
matrix-detached cells in the analysis and made it easier to visualize using OPLS-DA 
models (Saei et al., 2018) (Figure 4). Finally, we built a database of anticancer drug 
response for 56 compounds in A549 adenocarcinoma cells and three datasets with 
increased analytical depth for 9 of the drugs in MCF-7, RKO, and A549 cells (Saei et 
al., 2019). The data can be explored through the ProTargetMiner web 
interface using OPLS models (http://protargetminer.genexplain.com).  
Figure 4. ProTargetMiner workflow using FITExP analysis. (a) Preparation of a dataset for FITExP analysis. 
The first step is to determine the IC50 of the compounds in the desired cell lines. Then cells are treated with 
IC50 including reference drugs, in this case, methotrexate (MTX), camptothecin (CAMP), and paclitaxel 
(PCTL) in addition to the compounds of interest and the vehicle. Then cells are lysed, proteins are digested, and 
the resulting peptides are labelled with TMT10, off-line fractionated, and analysed by LC-MS/MS. These steps 
can be done label-free and without off-line fractionation. (b) Specific regulation of the target or target candidate 
for the drug of interest in comparison to other drugs. (c) OPLS-DA models highlight the mechanism of action 
and target of the drug of interest by contrasting it against all other drugs or against the reference drugs. Figure 
adapted from (Saei et al., 2019). 
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Stable Isotope Labelling by Amino acids in Cell culture (SILAC) is a type of 
metabolic labelling that can be utilized to tag proteins with stable isotopes in cells and 
in vivo for multiplexing and enhanced accuracy of protein abundances measurements 
(Krüger et al., 2008; Ong et al., 2002; Sury et al., 2010). However, SILAC is not only used 
for these features but also for the measurement of protein synthesis and degradation rates 
(Doherty et al., 2009). Indeed, pulse and pulse-chase SILAC strategies were rapidly 
implemented where cells or animals are fed with lysine and arginine labelled with stable 
isotopes of carbon and nitrogen. In pulse SILAC, the first labels are replaced by a second 
label at a specific timing, to quantify the portion of newly synthesized and degraded 
proteins over a certain period allowing to also calculate synthesis and degradation rates 
(Ong, 2012). SILAC can be combined with TMT for increasing multiplexing capacities, 
but only at the expense of high computational power and complicated spectra 
interpretation (Welle et al., 2016). Recently, Savitski et al. developed multiplexed proteome 
dynamics profiling (mPDP) (M. M. Savitski et al., 2018) for studying protein turnover in 
cells and, particularly, in the context of drug-mediated protein degradation. This is 
relevant for studying drug MOA and disease mechanisms (Fierro-Monti et al., 2013; 
Somasekharan et al., 2012). 
Lastly, subcellular fractionation methods coupled to LC-MS/MS can dissect the 
cellular proteome down to sub organelles and protein complexes using differential 
centrifugations and label-free or isotope labelling (Dunkley et al., 2004; Geladaki et al., 
2019; Itzhak et al., 2017). Since these methods were developed to be compatible with 
mass spectrometry, they enable unbiased detection of proteins present in specific cell 
locations. This is particularly valuable since cellular localization is fundamental to 
maintain the normal function of a protein and altered localization has been associated 
with diseases including cancer (Hung & Link, 2011; Rogaia et al., 1997; Xin et al., 
2014). Several studies have systematically classified proteins based on their 
expression and cellular localization and provided comprehensive visualization of the 
data (Christoforou et al., 2016; Itzhak et al., 2016; Joshi et al., 2019; Orre et al., 2019). 
These studies provide tools and unbiased spatial information on the organization of the 
cellular proteome in various cell types and stimulated conditions that are otherwise only 
available via time-consuming Western blotting or imaging techniques such as 
fluorescence microscopy.  
1.3.4 Study of PTMs 
One of the biggest challenges in the proteomics field is to accurately detect and 
quantify changes in post-translational modifications (PTMs) (M. S. Kim et al., 2016). The 
possibility of simultaneous detection of thousands of proteins makes LC-MS/MS the 
most appealing technology for large-scale studies of PTMs.  Nevertheless, most of the 
developed methods focus solely on one type of PTM and are based on enrichment of the 
native modification or enrichment of a tag specifically binding to the modification 
(Thygesen et al., 2018). Computational tools for the detection of any PTMs in complex 
proteomics samples have also been implemented (Devabhaktuni et al., 2019; M. M. 
Savitski et al., 2006). Yet, these workflows are mainly efficient for stable modifications 
only. In addition, the PTM occupancy is rather low in most cases, hindering their 
identification. As a result, mostly unmodified peptides are identified.  
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Redox proteomics faces similar issues. Several mass spectrometry-based technologies 
aimed at studying various proteins’ redox-related modifications have also been 
implemented for irreversible modifications (J. Yang et al., 2016). Nonetheless, 
studying other types of modifications is challenging due to their rapid dynamics. 
Indeed, these PTMs can often be enzymatically reverted by the antioxidant systems. 
Moreover, some of these PTMs occur in vitro during sample preparation such as 
oxidation of methionine that is routinely added to proteomics search engines in shotgun 
experiments due to its high occurrence rate (Nielsen et al., 2006). These characteristics 
stress the need to “freeze” the modification on the protein. This approach can be similar 
to the strategy used in phosphoproteomics where kinases and phosphatases are heat-
inactivated to avoid the removal of the phosphorylation (Humphrey et al., 2018). 
The importance of disulfide bond formation for protein structure promoted the development 
of labelling-based strategies to study system-wide cysteine oxidation. Among such labels, 
iodoTMT (Qu et al., 2014), iTORC (Albertolle et al., 2019), CysPat (H. Huang et al., 2016), 
and SICyLIA (Van Der Reest et al., 2018), were successful in addressing the issue since the 
chemical tags can be added directly to the lysis buffer. Indeed, these tags irreversibly bind to 
reduced cysteines preventing further modification during sample preparation. The first step is 
to label reduced cysteines in the cells with the first tag (Figure 5). Then, oxidized cysteines 
are reduced with a reducing reagent such as DTT and labelled with a second tag. The 
proportion of oxidized to reduced cysteines in different conditions is accurately measured by 
the reporter ion intensity (Figure 5). One of the drawbacks of these methods is that they erase 
or disregard the information about the identity of the modifications that are present on the 
cysteines. Reversible cysteine modifications include disulfide formation (Sevier & Kaiser, 
2002), nitrosylation (Fernando et al., 2019), sulfenylation (Devarie-Baez et al., 2016), 
glutathionylation (Grek et al., 2013), persulfidation (Kasamatsu et al., 2016), polysulfidation 
(Kasamatsu et al., 2016) and palmitoylation (Jin et al., 2021). Cysteine labelling methods 
summarize all these modifications into a single readout. In addition, hardly reversible or 
irreversible cysteine modifications such as sulfinylation and sulfonylation (Beedle et al., 
2016; Chauvin & Pratt, 2017; Van Bergen et al., 2014), will be completely left out of the 
analysis due to the impossibility to reduce them and to subsequently label the reduced thiol 
(Day et al., 2021). Consequently, the interpretation of the results of such analysis should 
always be considered with caution as they could be subjected to over or misinterpretation. 
Finally, cysteine-containing peptides need to be detected. This is not always the case in LC-
MS/MS-based proteomics, since only a fraction of the peptides from a protein can be 
measured. One unique advantage of CysPat is that the tag contains a phosphate group and 
thus the enrichment strategy is the same as in phosphoproteomics, allowing one to study in 
parallel the crosstalk between redox signalling and phosphorylation cascades. 
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Figure 5. Labelling of cysteine-containing proteins by iodoTMT. Scheme of the labelling strategy used in 
redox proteomics to measure cysteine oxidation levels in peptides. Cells are lysed and a first TMT is added to 
bind to the reduced thiol on cysteines. Then oxidized cysteines are reduced with a reducing agent such as DTT 
and labelled with a second TMT. Proteins are digested and peptides are analysed by LC-MS/MS. The MS/MS 
intensity from both TMTs allows calculation of the oxidation and reduction levels for each peptide. 
1.3.5 Methods based on limited proteolysis 
One of the unique advantages of mass spectrometry-based proteomics over other existing 
technologies is that it enables the proteome-wide study of protein conformational changes 
reflected on protein stability. Several methods have been developed to address the issue, for 
instance, Drug Affinity Responsive Target Stability (DARTS) (Lomenick et al., 2009). This 
technique is based on the same principle as pulse proteolysis classically used with Western 
blot (Park & Marqusee, 2005). DARTS relies on the fact that the binding of a drug will cover 
enzyme-cutting sites resulting in a difference in levels of the covered peptides in shotgun 
proteomics compared to a non-treated condition. Since only peptides that are in contact with 
the chemical are affected, it is also possible to pinpoint the location of the binding site. 
DARTS has been routinely used for detecting binding events of small molecules on proteins 
or protein-protein interactions in multiple diseases and organisms (Cai et al., 2018; Gautam et 
al., 2018; Geng et al., 2019; Lazarev et al., 2018; Q. Li et al., 2018; Nampoothiri & 
Rajanikant, 2019; Rodriguez-Furlan et al., 2017; Tanie et al., 2018; Z. Yang et al., 2017).  
Another method that relies on a similar principle is Limited Proteolysis coupled to MS 
analysis (LiP-MS) (Feng et al., 2014; Schopper et al., 2017). Usually, trypsin or lysyl 
endopeptidase (LysC) is used to produce peptides needed for bottom-up analysis. Here the 
first digestion with a broad protease such as proteinase K produces unspecific peptides 
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enabling the detection of structural changes. LiP-MS was employed in yeast to study 
conformational alterations occurring in around 300 proteins upon changes of growth 
conditions (Feng et al., 2014). Interestingly, the authors of the study could detect both subtle 
and more permanent conformational changes. Subsequently, the authors studied changes in 
protein conformation associated with heat shock and showed that a specific subset of proteins 
is denatured when cells reach temperatures that begin to reduce their fitness (Leuenberger et 
al., 2017). Since then, LiP-MS was used to highlight protein-metabolite and protein-protein 
interactions (Piazza et al., 2018), to detect the binding site of a drug (Piazza et al., 2020) or 
nanoparticle (Duan et al., 2019) on a protein and, in general, to detect chemical modifications 
that do not necessarily alter protein levels (Cappelletti et al., 2021; de Souza & Picotti, 2020; 
Pepelnjak et al., 2020). However, one of the drawbacks of both DARTS and LiP-MS is that 
only a fraction of the proteome can be analysed due to the limitations of enzymatic digestion. 
In addition, specific peptides mapped at the site of the conformational change are sometimes 
not identified. These caveats greatly cripple the use of these methods in a high throughput 
context and for analysis of low abundant proteins.  
1.3.6 Protein thermal stability measurements 
The Cellular Thermal Shift Assay (CETSA) has been developed to monitor protein thermal 
stability using Western blot (Jafari et al., 2014; Molina et al., 2013). CETSA is based on a 
previously described technique to detect the binding of a chemical to a purified protein by 
measuring changes in thermal stability (Pace & McGrath, 1980; Pantoliano et al., 2001). 
Briefly, cell lysates, whole cells, or animals (Molina et al., 2013) are treated with the 
compound of interest and vehicle control. Then, samples are aliquoted and heated with a 
temperature range, usually from 37 to 67°C, which will cause proteins to gradually unfold 
and aggregate. The aggregates are cleared by centrifugation and the soluble fraction is then 
analysed by Western blot to record the melting profile of the proteins of interest. A thermal 
shift between the samples treated with the drug and the samples treated with the vehicle 
highlights protein-drug interaction. Importantly, animal experiments (and cell experiments to 
some extent) also include pharmacokinetics aspects that are crucial for drug development. 
Nonetheless, this approach relies on a priori knowledge of drug targets. The existence of 
suitable antibodies against the target of interest is also a requirement in CETSA. Recently, the 
method was used to screen for thymidylate synthase inhibitors in a high throughput setup and 
successfully identified new inhibitors (Almqvist et al., 2016). 
TPP or MS-CETSA was adapted from CETSA as an LC-MS/MS-based method, turning 
CETSA into a proteome-wide and unbiased approach (M. M. F. Savitski et al., 2014) (Figure 
6). Using TMT10 labelling, the authors were able to record protein melting profile of >7000 
proteins and to accurately identify multiple targets of kinases inhibitors. Moreover, one of the 
advantages of TPP is that it can measure downstream effects of protein target inhibition in the 
cell experiments and differentiate them from direct interaction with the drug in the lysate 
experiment. 2-dimensional TPP (2D-TPP) was also introduced to simultaneously monitor 
temperature as well as drug concentration-dependent protein unfolding (Becher et al., 2016) 
(Figure 6). TPP discovered FECH as the off-target of several kinase inhibitors, explaining 
light-sensitivity experienced by treated patients (M. M. F. Savitski et al., 2014). The method 
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was also used to study the binding of metabolites, such as ATP and GTP and was adapted to 
increase the recovery of membrane-bound proteins using a low concentration of detergent 
(Reinhard et al., 2015). Later, TPP was adapted for deconvolution of targets of antibiotics in 
bacteria (Mateus et al., 2018), was used to study ROS effect on protein structure (Sun et al., 
2019), and correlated thermal stability changes to phosphorylation (J. X. Huang et al., 2019). 
In a more biological context, TPP was employed to monitor protein stability changes 
associated with different phase-transitions of the cell cycle (Becher et al., 2018; Dai et al., 
2018). Finally, TPP was used to study the effect of genetic mutations on protein thermal 
stability (Mateus et al., 2020; Peck Justice et al., 2020) and was used to monitor drug-protein 
interaction in treated animals (Perrin et al., 2020). 
Overall TPP opens new possibilities in mass spectrometry-based chemical proteomics 
because of its versatility and adds a new dimension in studying protein characteristics. 
However, there is a lot of room for improvement of the method as it lacks throughput and, 
therefore, is costly to use. Another drawback is that TPP involves arbitrary curve fitting in 
most cases (Franken et al., 2015; Jarzab et al., 2020; Kalxdorf et al., 2021; Leijten et al., 
2021; Mateus et al., 2018; Peck Justice et al., 2020; Reinhard et al., 2015) (Figure 6). The 
problem of this model is that the sigmoidal curve fitting equation is designed for proteins that 
have an expected and predefined melting behaviour characterized by a decrease in solubility 
with an increase of temperature, which is not the case for all proteins. The same issue also 
arises for highly stable proteins that do not unfold at the maximum temperature. This 
inevitably leads to an absence of curves and estimated melting temperature (Tm) for a lot of 
proteins. New methods for the analysis of TPP output are under development to 
overcome this limitation. In 2D-TPP for example, (Becher et al., 2018) established a 
scoring system relying on a bootstrap algorithm and FDR calculations to set up 
cut-offs for significance. However, this approach still relies on complex calculations and 
the field would benefit from a simplified method that could be widely used. 
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Figure 6. Scheme of the 
various versions of TPP. 1) 
Intact cells or cell extracts are 
prepared. 2) Then drug 
treatment is performed either in 
single (TPP-TR) or multiple 
concentrations (TPP-CCR and 
2D-TPP). 3) Samples are 
heated with a single 
temperature (TPP-CCR) or a 
temperature range (TPP-CCR 
and 2D-TPP). 4) Cell lysis is 
performed and followed by 
centrifugation to eliminate 
protein aggregates. 5) Soluble 
proteins are digested, then 
peptides are labelled with 
isobaric tags, and samples are 
multiplexed. 6) Samples are 
analysed by LC-MS/MS. 7) 
Data processing involves 
sigmoidal curve fitting for TPP-
TR and TPP-CCR while 2D-
TPP uses 2-dimensional 
heatmaps of protein FC and a 
different scoring system 
(Becher et al., 2018). Reprinted 
from (Mateus et al., 2016). 
1.4 PROTEOMICS ATLASES 
With technical development in proteomics, most conventional approaches have improved in 
throughput and analytical depth, which opened the possibility of creating atlases or resources 
of increasing complexity. These resources were focused on various systems and proteomics 
dimensions. In some resources, protein expression was measured in various cell types or 
tissues and authors have measured protein expressions in up to 375 different cancer cell lines 
(H. J. Johansson et al., 2019; Nusinow et al., 2020; D. Wang et al., 2019). We also produced 
the ProTargetMiner resource (Saei et al., 2019). ProTargetMiner is the first connectivity map-
like resource in proteomics and allows to explore protein expression variation upon 
anticancer treatment of 56 drugs with some measured in several cell lines. Expression 
measurements were also used to determine protein subcellular localization with multiple 
comprehensive resources (Christoforou et al., 2016; Itzhak et al., 2017; Joshi et al., 2019; 
Orre et al., 2019). In another study focused on drug target deconvolution, kinobeads were 
utilized to evaluate the target landscape of 234 kinase inhibitors approved for therapeutic use 
in clinics or involved in clinical trials (Klaeger et al., 2017). Now that other dimensions have 
been defined in proteomics, other atlases such as the Meltome atlas have been produced 
(Jarzab et al., 2020) where the authors measured protein thermal stability using TPP across 
several cell lines and 13 different species, from archaea to human. The functional landscape 
of E. Coli was also studied by analysing 121 genetic alterations in E. Coli using TPP (Mateus 
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et al., 2020). Finally, a combination of multiple disciplines including genome engineering led 
to a tour de force analysis of 1311 CRISPR-edited cell lines to study protein localization (Cho 
et al., 2021). These extensive resources are valuable for the proteomics community as well as 
for biological sciences in general as they offer the possibility to other researchers to analyse 
pre-existing multidimensional datasets without the cost of producing them. However, while 
increased throughput and analytical depth allowed for such studies, they are only possible in a 
handful of research laboratories as they demand a consequent analysis time, material and they 
increase the data analysis burden. Therefore, new developments in higher throughput 
methods and simplified analysis and visualization tools are still highly needed. 
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2 RESEARCH AIMS 
2.1 MAIN OBJECTIVES 
The main objectives of the present work were to develop new mass-spectrometry-based 
proteomics methods and visualization strategies and combine them with pre-existing 
methods to study the cellular dynamics and the mechanisms of anti-cancer 
compounds. These methods were developed to uncover the unknown mechanisms of 
action and targets of promising anti-cancer treatments as well as to discover biomarkers 
playing a role in cell type transitions that can be targeted to modulate cell fates.  
2.2 SPECIFIC AIMS OF THE THESIS 
1- To study cellular dynamics in in vitro cell culture using proteomics methods (papers
I and V).
2- To further develop proteomics approaches for drug target deconvolution and for
target discovery (papers II and V).
3- To combine proteomics approaches to uncover molecular clues on drug treatment and
cellular events (papers III, IV, and V).
4- To merge proteomics analysis and create a new data visualization tool (paper V).
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3 MATERIALS AND METHODS 
3.1 CELL CULTURE 
We mainly used human and mouse cancer cell cultures which were maintained in a medium 
consisting either of DMEM or RPMI supplemented with 2 mM L-glutamine when not 
included in the formulation, 100 units/ml of penicillin/streptomycin mix, and 10% FBS, this 
was the case for papers I, II, and III. In paper IV the medium was supplemented with an 
additional 250 nM sodium selenite to avoid potential variation in selenium supplementation 
from different FBS batches (Leist et al., 1996). Finally, in paper V only two cancer cell lines 
were used throughout the article, and hFF, iPSCs, human embryonic stem cells (ESC), 
neurons, and EBs were used there. For pluripotent stem cells and differentiation protocols, a 
medium was specially formulated as described in the method sections of the articles. Various 
coating materials were also used including laminin 521, laminin 511, poly-L-ornithine, 
gelatin, and Matrigel as well as various small molecule inhibitors. 
3.2 LABEL-FREE PROTEOMICS 
Label-free proteomics is the classical quantification approach used in shotgun proteomics. In 
short, peptides are extracted from the cells with detergent (SDC, SDS) and/or chaotropic 
agents (Urea) then proteins are reduced using DTT and alkylated using iodoacetamide (IAA), 
digested overnight by LysC and for 6 h by sequencing grade trypsin. Then samples are 
desalted using C18 resins and injected into a liquid chromatography system coupled to a mass 
spectrometer. In this case, each individual sample is analyzed separately. The absence of 
intermediate steps in the protocol makes it faster than labeling-based methods for sample 
preparation. Label-free proteomics was used in papers I, III, and V. 
3.3 TMT LABELING 
Contrary to label-free proteomics, in label-based shotgun approaches, samples are labeled 
with a chemical tag. This allows us to identify the samples and multiplex them to save LC-
MS/MS analysis time and reduced the missing values between samples in the same set. In 
papers I, II, III, IV, and V we used a combination of various TMTs, TMT10 in all articles, 
TMT11 in paper V, and iodoTMT in papers III and IV. Classical TMTs react to primary 
amines while iodoTMTs comprise a cysteine reactive group that binds to cysteines (Figure 7). 
Instead of measuring peptide abundance, sequential iodoTMT labeling allows the 
measurement of cysteine oxidation levels on peptides. The protocol is different for both 
versions. For TMT samples after cell lysis, equal amounts of proteins are reduced with DTT, 
alkylated with IAA, and samples are cleaned using methanol chloroform protein precipitation 
to exchange buffer, and then they are resuspended into 8M urea and EPPS. Since TMTs label 
free amine groups, buffers such as ammonium bicarbonate or Tris cannot be used for 
labeling. Then, samples are digested overnight with LysC and then 6 h with trypsin. 
Subsequently, TMTs were added corresponding to four times the protein amount in the 
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samples and ACN is added to the samples to a concentration of 20% to facilitate labeling. 
The reaction is quenched using 0.5% hydroxylamine and samples are combined. For PISA-
Express a pooled sample corresponding to one-tenth of each sample was created as a linker, 
labeled with TMT11, and used for normalizing protein abundances between TMT11 sets.   
Figure 7. Structure of the Tandem Mass Tag. The isobaric mass tag consists of a mass reporter, a mass 
normalizer, and a reactive group. The difference between TMT (a) and iodoTMT (b) lies in the reactive group. 
TMT reacts to primary amines (NH2) while iodoTMT reacts to cysteines exclusively and thus measurements are 
limited to cysteine-containing peptides only. A different number of carbon-13 and nitrogen-15 (red star) are 
positioned on the mass reporter to identify different tags thanks to the mass difference. The weight of the tag is 
balanced by the mass normalizer in the opposite way so that the overall mass is the same for each tag. Because 
of this, only one mass is detected in a full MS spectrum for a mixture of the same peptides labeled with different 
TMTs (c). The mass reporters are detached during ETD or HCD fragmentation for MS/MS and each of them 
produces a unique mass signal. The intensity of the reporter ion signal corresponds to the abundance of the 
peptide allowing deconvolution of the multiplexed samples and relative quantification.  
3.4 HIGH-PH REVERSED-PHASE PEPTIDE FRACTIONATION 
Sample multiplexing allowed for off-line pre-fractionation of the samples. One of the main 
issues in data-dependent acquisition is that the dynamic range of protein abundance leads to 
the overrepresentation of abundant proteins in spectrums. Thus, to circumvent this problem 
samples can be fractionated with an orthogonal method to reversed-phase low-pH 
chromatography to split the LC gradient into several containing a portion of the peptide 
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population only. One of the most common methods is high-pH reversed-
phase chromatography that is semi-orthogonal to its low pH counterpart. This is what was 
used in all the articles presented in this thesis, either using Pierce™ High pH Reversed-
Phase Peptide Fractionation Kit (Thermo Fisher Scientific) resulting in 8 fractions 
(papers III and V) or 100 to 250 µg of peptides were injected into an UltimateTM 
3000 RSLCnano System (Dionex) equipped with an XBridge Peptide BEH 25 cm 
column of 2.1 mm internal diameter, packed with 3.5 µm C18 beads with 300 Å pores 
(Waters). Peptides were eluted with a buffer A (20 mM NH4OH in H2O) and B (100% 
ACN) from 1% to 63% B and collected into 96 fractions which were then concatenated 
into 12-24 (papers I, II, IV, and V).  
3.5 MASS SPECTROMETRY ANALYSIS 
Various instruments and LC systems were used in the articles presented in this thesis. In 
terms of the mass spectrometers, we used Orbitrap Q Exactive, Orbitrap Q Exactive plus, 
Orbitrap Q Exactive HF, Orbitrap Elite, Orbitrap Fusion, and Orbitrap Fusion Lumos (all 
from Thermo Fisher Scientific). In terms of LC systems, we used the EASY-nLC-1000 
system (Thermo Fisher Scientific) and the nanoflow Dionex Ultimate 3000 UPLC system 
(Thermo Fisher Scientific). Both systems were connected to an EASY-spray column (50 cm, 
75 µm inner diameter, 2 µm PepMap C18 beads of 100 Å size). Peptides were resuspended 
into 0.1% formic acid (FA) and 2% acetonitrile (ACN) in H2O buffer and around 1 µg of 
peptide per sample or fraction was injected into the LC system. The gradient consisted of a B 
phase (98% ACN, 2% H2O, 0.1% FA) ranging from 2% to 26-36%. The acquisition was 
performed on data-dependent mode and the various parameters are detailed in the method 
section of each article. The major difference was that the resolution minimum for MS/MS 
had to be higher for TMT-labeled samples (minimum 35 000) and the isolation window 
lower 0.7 to 1.6 Da while it was 3 Da for label-free analysis.  
3.6 PROTEIN QUANTIFICATION 
All LC-MS/MS data were analyzed with several versions of MaxQuant software using the 
Andromeda search engine. For TMT/iodoTMT-based experiments, MS/MS quantification 
was selected while LFQ was selected for label-free. Carbamidomethylation of cysteine 
was selected as a fixed modification for samples that were not labeled with iodoTMT. For 
iodoTMT, no fixed modification was selected, iodoTMT was selected as MS/MS 
quantification instead. Oxidation of methionine and deamidation of asparagine and 
glutamine were selected as variable modifications for all types of samples. Trypsin/P was 
selected as the enzyme with up to two missed cleavages. The FDR was set to 1% for 
peptides and proteins and for the rest of the parameters we used the default settings of the 
software. The “Match between runs” option was selected with a time window of 0.7 min 
and an alignment time window of 20 min for each analysis including multiple samples 
or TMT sets. Finally, data were searched against either human or mouse protein 
databases from Uniprot. The reference is indicated in the method section of the articles. 
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3.7 DATA ANALYSIS 
Quantification data from MaxQuant were analyzed with Excel and R. SIMCA was used for 
OPLS-DA modeling. Raw protein abundances (or intensity of TMT reporter ion) for each 
sample were normalized by the total abundance of all proteins in the sample except for TPP 
experiments where protein abundances were normalized by the average abundance of the 
proteins in the 37ºC and 41ºC temperature points in the corresponding TMT10 set. In PISA-
Express, each protein abundance was also normalized by the corresponding TMT11 linker 
protein abundance prior to sample comparison, to remove batch effects. 
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4 RESULTS AND DISCUSSION 
4.1 DYNAMIC PROTEOMICS REVEALS HIGH PLASTICITY OF 
CELLULAR PROTEOME: GROWTH‐RELATED AND DRUG‐
INDUCED CHANGES IN CANCER CELLS ARE COMPARABLE. 
In paper I, we studied cellular proteome dynamics in in vitro cancer cell cultures treated by 
anti-cancer drugs, vehicle and untreated. The rationale behind these experiments is that in 
vitro cell culture is widely used throughout biological sciences and it is considered a stable 
and controlled system. Time series analysis usually contains time-matched controls, but it is 
not always the case as the effects of cell culture variations on the proteome are often 
overlooked since they are not necessarily visible phenotypically. Here we aimed to 
investigate the magnitude of these proteome changes and compare them to changes 
associated with anticancer drug treatment at IC50 concentration. 
4.1.1 Proteome changes in the control group are equivalent to drug 
treatment at IC50 after 48 h. 
To study the magnitude of proteome changes over time, we treated HCT116 cancer cells with 
MTX, paclitaxel (PCTL) at IC50, and the equivalent concentration of vehicle, 
dimethylsulfoxide (DMSO), for 48 h and collected samples at the start of the experiment and 
every 6 h. We measured protein abundances using label-free proteomics for 2116 different 
proteins quantified in all samples. To monitor proteome variation, we plotted the abundance 
changes using PCA (Figure 8a). We observe clear separation from the control sample group 
after 12 h and even some noticeable separation after 6 h of treatment for MTX and PCTL. 
The x-axis corresponding to PC1 seemed to reflect the variation over time and MTX had the 
higher variation after 48 h of treatment. Strikingly, the control group starts to also show 
separation after 12 h. The changes in the DMSO-treated control group at 48 h are on par with 
those in PCTL treatment. This was confirmed by examining the number of proteins showing 
significant changes at the various time points, where DMSO control numbers were on par 
with PCTL treatment (Figure 8b). This was particularly unexpected since the treatments that 
we used were at IC50 and thus highly lethal for the cells, while the concentration of DMSO 
was 4.5 ppm likely to be negligible. These changes in the control group are gradual with a 
maximum at 48 h and are likely to arise from phenomena such as cell division, degree of 
confluence, acidification of the medium.  
Figure 8: Proteome variations upon chemical treatment. (a) PCA of the 2116 proteins that were quantified in 
all samples for MTX, PCTL, and vehicle treatments (DMSO). (b) Number of proteins with p-value <0.05 
calculated using an unpaired t-test against T0. Figure adapted from (Sabatier et al., 2018). 
26 
4.1.2 Proteome changes are not due to chemical treatment and are not cell 
line-specific. 
Since in the pilot experiment the control group was still treated with DMSO we decided to 
study changes associated only with cell growth. To investigate naturally occurring variation 
in in vitro cell culture, we did not treat the cell lines that were tested this time. Additionally, 
to demonstrate that these changes are not cell-line specific only, we monitored the 
proteome of A375 and HCT116 for 48 h, collecting samples every 12 h starting 24 h 
after plating. To obtain a deep picture of the proteome evolution we chose to label 
samples with TMT10 labeling and multiplex them. This allowed us to fractionate the 
samples using high-pH reversed-phase peptide fractionation. We obtained quantitative 
data for 8898 proteins identified with at least two peptides. To evaluate proteome 
changes we only considered reproducibly quantified proteins with a coefficient of 
variation < 15% between replicates resulting in 6053 proteins. The resulting expression 
changes comparing each time point to the start of the experiment (T0) show that the 
proteomes of both cell lines start to change as early as 12 h and continue to gradually drift 
until 48 h (Figure 9). Importantly, the magnitude of the changes was similar in both cell 
lines. Thus, we concluded that the general proteome changes happen regardless of chemical 
treatment and are not cell line dependent.  
Figure 9. Gradual expression changes in A375 and HCT116 cells during in vitro culture. Violin plots of 
log10 scaled expression fold change (FC) against the starting point T0. Figure adapted from (Sabatier et al., 
2018). 
4.1.3 Proteins involved in cell division and metabolism are the most 
regulated over time in in vitro cell culture. 
Finally, to investigate in detail whether specific pathways were activated or silenced over the 
course of the experiment, we used hierarchical clustering on the log scaled fold change (FC) 
at each time point against T0 followed by pathways enrichment using GO analysis of the 
clusters highlighted on the heatmap (Figure 10). The heatmap highlights pathways that are 
gradually upregulated and downregulated over time in both cell lines as well as cell line-
specific regulated pathways. Among the common regulated pathways, those that were 
downregulated include mainly proteins that are linked to cell division, DNA replication, and 
ribosome biogenesis while upregulated pathways encompassed proteins involved in the 
oxidation-reduction process, cellular respiration, and organic acid metabolism. Therefore, the 
general trend was downregulation of pathways linked to cell division and upregulation of 
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pathways linked to energy production and metabolism. Strikingly, proteins involved in 
cell division were downregulated already starting from 12 h. This data, in light of the low 
confluence of cells suggest that cell division is affected even during what is 
commonly considered the exponential growth phase. 
Figure 10. Proteome variation in A375 and HCT116. Heat map of mean protein log2 scaled FC at each time 
point compared to T0 (left) and fold enrichment of GO processes, with bars colored according to the average 
log2 scaled FC compared to T0 at 48 h for both cell lines combined (right). Figure reused from (Sabatier et al., 
2018). 
Conclusions 
We studied the evolution of the cellular proteome over time in in vitro cell cultures treated 
with anticancer drugs MTX and PCTL, with DMSO and untreated. Our observations show 
that naturally occurring variations of the proteome are on par with variations induced by drug 
treatment at IC50. We also demonstrate that these changes are not cell type-dependent and 
emphasize the use of time-matched control in cell experiments. Importantly, the expression of 
proteins involved in the cell cycle and cell division was altered even at a low confluence. 
Finally, we provide a magnitude for this change as well as a deep dataset that can be explored 
for studying proteome changing happening over time in in vitro cell culture. 
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4.2 PROTEOME INTEGRAL SOLUBILITY ALTERATION: A HIGH-
THROUGHPUT PROTEOMICS ASSAY FOR TARGET 
DECONVOLUTION. 
Approaches based on measurement of protein solubility following a gradient or stepwise 
increase of the protein solubility-altering factor often rely on curve-fitting as a readout. TPP 
is one of the most prominent examples of such methods (Franken et al., 2015; M. M. F. 
Savitski et al., 2014). In 1D TPP (TPP-TR or TPP-CCR), cells or cell lysates can either be 
subjected to a fixed drug concentration and a temperature range or vice versa. While in 2D-
TPP both a varying drug concentration and temperature gradient are used (Becher et al., 
2016). In many cases, variations in protein thermal stability are primarily estimated based on 
the melting temperature (Tm) difference of a protein between two conditions. The Tm 
corresponds to the temperature where 50% of the pool of a protein is soluble and 50% is 
insoluble compared to the lowest temperature of the range. Tms are used to visualize the 
entire dataset on volcano plots for example, while curves can only be individually inspected. 
One of the issues with this approach is that only proteins with sigmoidal melting behavior can 
have a Tm estimate and thus many proteins that do not follow this pattern are disregarded in 
the analysis. Another problem is that in the 1D version, for one replicate, up to 10 
temperature or concentration points are measured both for the control and treated condition 
while the Tm analysis generates only one data point. Thus, in paper II, we aimed to develop 
an alternative to curve-fitting and integral-based methods in proteomics and particularly 
protein solubility-based methods by combining the samples over a focused temperature range 
prior to analysis (Figures 11a, b, and c). The resulting method, Proteome Integral Solubility 
Alteration (PISA) assay considerably increases the throughput and reduces the amount of 
material and instrumental cost needed for such studies, and provides an easy readout. 
Figure 11. Schematic of PISA compared to TPP. (a) A focused temperature range is selected in the sigmoidal 
part of protein precipitation curves. Sm, Sm’ and ΔSm being the area under the curve of the vehicle, compound 
and the difference between these two areas, respectively. (b) Samples corresponding to multiple temperature 
points are pooled. (c) ΔSm highlights the difference in the area under the curve between the vehicle and control. 
Adapted with permission from (Gaetani et al., 2019). Copyright (2019) American Chemical Society. 
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To verify that our approach could work, we first used theoretical calculations and calculations 
based on the available TPP datasets. We demonstrate that calculating the difference between 
the integral of the curves and the Tm differences highly correlate with R2 of 0.999, 0.999 for 
theoretical measurements of temperature range and concentration range experiments, 
respectively. Then we also show that Tm differences and integral differences also correlate 
using data from published datasets with R2 of 0.897 and 0.975 for TPP in cell and cell lysate, 
respectively (M. M. F. Savitski et al., 2014) (Figure 12a-f). This confirmed that analysis of 
the integral is as valuable as the analysis of the Tm.  
Figure 12. Theoretical calculations using pre-existing TPP datasets. (a), (b), (c) Volcano plots of ΔTm, ΔSm 
and 2-dimensional plot of ΔSm against ΔTm of intact cells treated with 5 µM dasatinib. (d), (e), and (f) same 
plots but in cell lysate. Data were extracted from a study by (M. M. F. Savitski et al., 2014). Reprinted with 
permission from (Gaetani et al., 2019). Copyright (2019) American Chemical Society.  
Then we used well-studied drugs MTX and 5-FU as model drugs for our proof-of-concept 
experiment. We show using PISA with a focused temperature range, that DHRF and TYMS, 
respective targets of MTX and 5-FU, are identified as outliers in cell and lysate experiments 
(Figure 13). To showcase the higher throughput of the method, we analyzed 9 drugs in one 
TMT10 set per replicate and highlighted some of their targets. Finally, we show that 
concentration range analysis can be added to the measurements using only 3 samples 
(control, temperature range, concentration range) hosting an entire experiment in triplicate in 
one TMT10 set. 
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Figure 13. 1D PISA highlights targets of methotrexate and 5-fluorouracile. 1D PISA analysis of A549 
treated with MTX in intact cell (a) and cell lysate (b). (c) 1D PISA analysis of A498 cells treated with 5-FU. 
Reprinted with permission from (Gaetani et al., 2019). Copyright (2019) American Chemical Society. 
Conclusions 
We developed a higher throughput assay for condensing data from dose-response curves 
and demonstrated its potential using TPP analysis as an example. The assay also 
uses less material than TPP, greatly reducing the cost of such analysis. The temperature 
range can be easily adapted to better fit a particular cell system as in TPP. This type of 
strategy can be used in various contexts such as in limited proteolysis, in various 
protein precipitation strategies including chaotropic agents, pH, temperature, pressure, 
salt concentration. In summary, these advantages make PISA analysis highly suitable 
for large-scale studies that are becoming a routine in the proteomics field. Here we 
also show that PISA can be complementary to FITExP in a first attempt to combine our 
in-house methods. 
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4.3 COMPREHENSIVE CHEMICAL PROTEOMICS FOR TARGET 
DECONVOLUTION OF THE REDOX ACTIVE DRUG 
AURANOFIN. 
In paper III, we combined our in-house FITExP analysis with TPP and redox proteomics to 
study in detail the targets and MOA of AF. AF has been used primarily in the treatment of 
rheumatoid arthritis (Borg et al., 1988; Graham et al., 1991; N. H. Kim et al., 2010). 
However, it has regained interest in recent years as a potential anti-cancer drug and is 
now/was in clinical trials for several types of cancer (https://clinicaltrials.gov/). Multiple 
targets and MOAs have been described (De Luca et al., 2013; N. Liu et al., 2014; Tian et al., 
2019) for the drug and particularly it is known to bind to and inhibit TXNRD1 (Marzano et 
al., 2007; Stafford et al., 2018; Zhang et al., 2019). Here we took on the task of elucidating 
the targets and MOA of AF in detail using chemical proteomics approaches. 
4.3.1 Combination of chemical proteomics methods predicts auranofin 
targets and mechanism of action. 
First, we performed FITExP analysis using MTX and PCTL as referenced drugs in HCT116, 
A375, and RKO cell lines, TPP in HCT116 cells, and cell lysate and redox proteomics in 
HCT116 (Figures 14a, b, and c). Proteins were ranked according to their regulations in each 
of the experiments and the individual rankings were combined into a final ranking. The top 
three proteins in the combined ranks were NFKB2, CHORDC1, and TXNRD1, respectively 
(Figure 14d). The proteins showed alteration in either or all analyses of expression, oxidation 
level, and thermal stability (Figures 14e, f, and g). The presence of TXNRD1 in the top 3 of 
the combined ranking of all analyses performed confirmed the utility of the combined 
approach for drug target deconvolution since it is known as a target of AF. Indeed, TXNRD1 
ranked at best at 15th position in FITExP analysis demonstrating that individual methods 
failed to accurately deconvolute it as a very top target hit. Additionally, NFKB2 is 
responsible for at least a part of AF anti-inflammatory effect and is known to be regulated by 
the TXRND1 system (Espinosa & Arnér, 2019; Flohé et al., 1997; Jeong et al., 2009), which 
is likely to explain its presence as the number 1 target hit. CHORDC1 presence as the 
number 2 target hit was mainly due to its high ranking in redox proteomics suggesting this 
might come from a downstream effect of TXNRD1 inhibition. Finally, the combined 
ranking for all methods was subjected to GO enrichment analysis. The results show 
that “oxidoreductase” is the top pathway, demonstrating that disruption of the redox 
balance is also part of AF general MOA (Figure 14h).  
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Figure 14. A combination of FITExP, TPP, and redox proteomics highlights auranofin target and 
mechanism of action. Hierarchical clustering of log2 scaled FC in FITExP (a) and cysteine oxidation ratios in 
redox proteomics (b). (c) TPP of auranofin in HCT116 cells. (d) Combined target ranking. (e), (f), (g) expression 
level, cysteine oxidation, and melting curves of the top 3 hits in ranking. (h) GO enrichment analysis using 
DAVID of the top 15 proteins in the combined ranking. Figure reused from (Saei et al., 2020). 
4.3.2 Peptide cysteine oxidation levels link to thermal stability alterations. 
Since TXNRD1 exerts many of its functions by reducing disulfide bonds in target proteins, 
we thought that modulation of such strong interaction would affect the overall stability of 
protein structure. Thus, we asked whether an increase or decrease in cysteine oxidation levels 
could be linked to changes in protein thermal stability. We plotted cysteine-containing 
peptides oxidation levels and highlighted peptides from proteins having a significant Tm shift 
in TPP analysis in cells. In total, 11 proteins that had altered thermal stability also had 
peptides with an increase or decrease in cysteine oxidation levels (Figure 15a). 
Next, we asked whether these peptides could be attributed to the active sites of the enzyme, 
which would demonstrate that inhibition of TXNRD1 modulates their function. Particularly 
peptides covering the active sites of SRXN1 and PRDX5 had increased cysteine oxidation 
levels and both proteins showed altered thermal stability in TPP with Tm of +4.5 ºC and -1.7 
ºC compared to DMSO treated control, respectively (Figures 15b and c). This showed that 
TPP could be used to detect post-translational modifications in accordance with previous 
observations (Becher et al., 2018; J. X. Huang et al., 2019; Sun et al., 2019). 
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Figure 15: Cysteine oxidation levels and protein thermal stability. (a) Volcano plot of cysteines oxidation 
levels compared to DMSO control, peptides belonging to proteins that also show thermal shifts in TPP are 
colored in purple. (b) Peptides from SRXN1 and PRDX5 showing a significant change in oxidation level (p < 
0.05) and sequence of the peptides highlighting the cysteine on the active site of the enzymes. (e) Melting curves 
of SRXN1, PRDX5, PHF5A, and RRM1. Figure adapted from (Saei et al., 2020). 
Conclusions 
A combination of chemical proteomics methods can uncover the target and MOA of a redox-
regulating drug. Importantly, when analyzing the results of each method individually, the 
main target of AF treatment, TXNRD1 is not a top target hit and they failed to identify it as a 
putative target. However, when all methods were combined, TXNRD1 appeared as a top 3 
candidate demonstrating the power of combined analysis. Lastly, we show that thermal shift 
can be linked to alteration of cysteine oxidation in proteins increasing the versatility of 
protein thermal stability measurements to detect PTMs.  
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4.4 COMPREHENSIVE CHEMICAL PROTEOMICS REVEALS THAT 
THE NEW TRI-1 AND TRI-2 COMPOUNDS ARE MORE 
SPECIFIC THIOREDOXIN REDUCTASE 1 INHIBITORS THAN 
AURANOFIN. 
Following the success of our strategy in paper III, we decided to further investigate redox-
modulating anti-cancer compounds. Two new Txnrd1 inhibitors, namely TRi-1 and TRi-2, 
have been recently identified and shown to have anticancer efficacy in mouse cancer models 
(Stafford et al., 2018) but their target landscape and MOA have not been investigated yet 
using unbiased approaches. Since we already studied Auranofin in human cancer cells and 
highlighted that its main mechanism of killing cells is likely to involve alteration of redox 
balance via Txnrd1 inhibition, we used AF as a reference point for the two other drugs. 
Considering the translational importance of our results for the understanding of effects in 
mouse cancer models, we used a similar combination of approaches with the treatment of two 
mouse cancer cell lines with several proteomics approaches, including FITExP, redox 
proteomics, and PISA developed in paper II instead of TPP. Additionally, we capitalized on 
our recent study of TXNRD1 substrates which showed that adding nicotinamide adenine 
dinucleotide phosphate (NADPH) as a co-factor with recombinant TXNRD1 enables the 
detection of disulfide bonds reduction by TXNRD1 in target proteins by TPP analysis (Saei et 
al., 2021). Thus, we added NADPH to one of the PISA in cell lysate experiment, representing 
another layer of information that could help reduce the number of potential false positive 
protein hits, by cross-validating the results with the other two PISA assays in cells and cell 
lysate. Finally, we previously showed that using OPLS-DA modeling to contrast one 
treatment against other treatments allows deconvoluting the drug MOA (Saei et al., 2018, 
2019). Therefore, we used this approach in FITExP adding MTX, CAMP, and PCTL to 
contrast with our drugs of interest. The overall scheme of the experimental strategy 
is described in Figure 16. 
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Figure 16. Combined chemical proteomics workflow. Protein expression and target specificity are measured 
by FITExP, PISA is used to evaluate early downstream effects, direct binding, and NADPH-dependent thermal 
shifts induced by the treatments. Redox proteomics measures cysteine oxidation levels in each treatment using 
iodoTMT labeling.  
4.4.1 A combination of chemical proteomics approaches shows that 
auranofin has a wider effect on the cellular proteome than TRi-1 and 
TRi-2 and all treatments trigger oxidative stress. 
First, we investigated the effect of each compound on the cellular proteomes of B16-F10 and 
LLC2 in FITExP and B16-F10 cell line only in PISA in cells and redox proteomics. We used 
B16 and LLC mouse cell lines as they can be used as tumor models in in vivo mouse 
experiments (D’Arcy et al., 2011; Kelkka et al., 2013; Winkelmann et al., 2006). Also, both 
the melanoma B16 and the lung adenocarcinoma LLC cells were earlier suggested to be 
dependent upon Txnrd1 for viability or tumor progression in mice (Hwang et al., 2015; Yoo 
et al., 2006; Zou et al., 2014). AF induced much higher variation in protein expression after 
48h of treatment compared to TRi-1 and TRi-2 (Figure 17a). GO analysis of the proteins that 
were significantly upregulated in both B16-F10 and LLC2 cell lines in each treatment shows 
that all treatment increases of proteins involved in oxidative stress (Figure 17b). Although AF 
had the proteins showing the widest thermal stability shifts, TRi-1 had a higher number of 
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proteins shifting in cells while TRi-2 had the least effect on protein thermal stability (Figure 
17c). Finally, all treatments had significantly higher cysteine oxidation levels than the DMSO 
control. TRi-2 showed the highest mean cysteine oxidation levels in peptides then Auranofin 
and finally TRi-1 (Figure 17d). Thus, redox proteomics showed that all treatments trigger 
oxidative stress and expression proteomics showed that they increase expression levels of 
proteins involved in oxidation-reduction processes probably as an adaptation of the cell to the 
treatments.  
Figure 17. Protein expression, stability, and cysteine oxidation alterations induced by auranofin, TRi-1, 
and TRi-2. (a) Hierarchical clustering and violin plots of expression FC of each drug against DMSO control in 
B16-F10 and LLC2 cell lines. (b) Two-dimensional plots of protein expression FC of each treatment in B16-F10 
against LLC2 (bottom) and GO pathways enrichment of the top up and downregulated proteins in both cell lines. 
(c) Violin plots of Sm FC from PISA analysis in B16-F10 cells. (d) Mean cysteine oxidation in treated samples,
measured by redox proteomics in B16-F10 cell line. p-values were calculated using an unpaired t-test, error bars
represent the standard deviation of the mean.
4.4.2 TRi-1 and TRi-2 are more specific Txnrd1 inhibitors than auranofin. 
We then used OPLS-DA models to highlight the specificity of the drugs toward Txnrd1, by 
contrasting each treatment against reference drugs MTX, camptothecin (CAMP), and PCTL 
in B16-F10 and LLC2, as in ProTargetMiner (Saei et al., 2018, 2019). The OPLS models 
highlight the specific regulation of various proteins involved in oxidation-reduction 
mechanisms (Figure 18). Txnrd1 ranked 28th, 76th, and 2810th in TRi-1, TRi-2, and AF 
treatments, respectively. Additionally, combined PISA analysis highlights 15, 37, and 38 
target hits for TRi-1, TRi-2, and AF, respectively (Figure 19 a). Thus, TRi-1 and TRi-2 are 
37 
more specific inhibitors of Txnrd1 than AF. Interestingly AF triggered high Nrf2 response as 
shown previously (Dunigan et al., 2018; Fuse et al., 2018; K. Johansson et al., 2017; N. H. 
Kim et al., 2010; Kipp et al., 2017), but not TRi-1 and TRi-2 suggesting that Txnrd1 
inhibition alone may not necessarily be enough to activate Nrf2. This is broadly in line 
with previous suggestions (Cebula et al., 2015), but suggests that Txnrd1 inhibition may 
combined with an additional, yet unknown, factor in order for Nrf2 activation to be 
triggered. 
Figure 18. FITExP analysis using OPLS-DA models of auranofin, TRi-1, and TRi-2. OPLS-DA models 
contrasting AF, TRi-1, and TRi-2 cell lines against MTX, CAMP, and PCTL treatments in B16-F10 and LLC2, 
various redox-related enzymes are highlighted including Txnrd1.  
4.4.3 Auranofin target landscape recapitulates some of the observed effects 
of the drug. 
The target landscape of AF included Eefsec, Mcmbp, Gsk3a, and Gsk3b (Figures 19a-d). 
Incidentally, AF also led to specific and strong downregulation of selenoproteins as 
previously shown (Talbot et al., 2008), which has not been shown for TRi-1 and TRi-2. 
Selenoprotein P (SELENOP) depletion is known to inhibit the synthesis of selenoproteins and 
likely through decreased availability of selenium for Eefsec-dependent selenoprotein 
translation (Burk et al., 2008; Chang et al., 1990; Christensen et al., 1994; Mostert et al., 
2003; Olsson et al., 1993). Thus, we hypothesized that AF inhibits Eefsec leading to a 
decrease in selenium incorporation in selenoproteins and their downregulation as a late 
response. Then, AF had Mcmbp as target hit stabilized in all three PISA experiments while 
members of the MCM complex were mostly destabilized. Mcmbp is known to disassemble 
the MCM complex likely by destabilizing each member (Nishiyama et al., 2011) and proteins 
that are in complexes are usually more stable than as free subunits (Tan et al., 2018). Mcmbp 
KD leads to the accumulation of DNA double-strand breaks (Quimbaya et al., 2014; 
Sedlackova et al., 2020) as does AF treatment (Boullosa et al., 2021). Thus, we hypothesized 
that the increased DNA double-strand breaks upon AF treatment stems from its effect on 
Mcmbp. Finally, AF altered the stability of Gsk3a and Gsk3b. Inhibition of these proteins 
leads to anti-inflammatory effects (Schrecengost et al., 2018) and AF was used in the 
treatment of rheumatoid arthritis (Borg et al., 1988; Graham et al., 1991; N. H. Kim et al., 
2010). Thus, anti-inflammatory properties of AF might originate in part from inhibition of 
Gsk3a and Gsk3b. 
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Figure 19. Combined PISA analysis. (a) Venn diagrams showing the number of shared target hits in each PISA 
in B16-F10 cells, cell lysate, and lysate + NADPH for AF, TRi-1, and TRi-2. (b), (c), (d) Volcano plots of Sm 
FC of Auranofin in PISA in cells, cell lysate, and lysate + NADPH, respectively.  
Conclusions 
Here we present a follow-up study of paper III adding our recently developed PISA and 
OPLS-DA modeling to our strategy for target deconvolution. We used AF and the recently 
discovered Txnrd1 inhibitors TRi-1 and TRi-2 and identified effects that are specific to 
Txnrd1 inhibition and drug-specific effects. According to our combined analysis, TRi-1 and 
TRi-2 are more specific inhibitors of Txnrd1. Additionally, our analysis highlight targets of 
AF treatment that explain part of its MOA in cells. Taken together our results and 
experimental design further demonstrate, in accordance with paper III, that a combination 
of chemical proteomics approaches is needed for obtaining comprehensive data about 
each treatment target and MOA as each analysis yielded additional layers of 
information. Additionally, using drugs that have Txnrd1 in common helped us 
deconvolute some of the mechanisms. Thus, a combination of chemical proteomics 
methods and drugs having the same targets proved to be valuable both for solving 
biological questions and to deconvolute specific drug mechanisms. 
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4.5 PLURIFACETED PROTEOMICS METHOD IDENTIFIES KEY 
REGULATORS OF TRANSLATION DURING STEM CELLS 
MAINTENANCE AND DIFFERENTIATION 
We showcased the methods that we developed in paper III and paper IV by investigating 
anti-cancer drugs targeting a protein which proved to be challenging due to its specific 
properties. In paper V we aimed to combine protein stability and expression dimensions in a 
more comprehensive analysis instead of studying them separately. First, we further develop 
PISA and employed it to investigate biological questions that are not involving drug 
treatment. The rationale behind that was to show that a similar combination of methods used 
in drug target deconvolution could also help deconvolute molecular mechanisms that happen 
during transitions of cells from one cell type to another. We reprogrammed hFF into iPSCs 
and differentiated them randomly through EB formation. We monitored protein expression 
and thermal stability after each transition and added human ESCs as control as well as well 
studied colon cancer cell line RKO that is dividing as fast as PSCs to verify that the 
differences that we observe are not coming from division rate bias (Figure 20). Thus, we 
obtained protein stability and expression data for 5 cell types in one TMT10 set. The general 
idea was that we could obtain an additional layer of information from the thermal stability 
measurement that is not accessible through protein expression only and could help us 
discover new specific features of PSCs. 
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Figure 20. PISA-Express workflow. (a) hFF were reprogrammed into iPSCs using the four Yamanaka factors 
(Takahashi & Yamanaka, 2006), then differentiated into EB. (b) Cell aliquots were heated, combined, lysed with 
NP40, and freezing-thawing and insoluble protein fraction was removed by ultracentrifugation. (c) Samples were 
multiplexed, and one-tenth of each sample was pooled to create a linker used for normalizing protein abundances 
between sets during data analysis. (d) Sm and Exp were calculated and plotted against each other, the resulting 
protein position of the plots determines their movement on the Sankey diagram.  
4.5.1 Protein stability and expression measurements distinguish cell types 
and various degrees of pluripotency. 
First, we asked whether thermal stability could distinguish cell types as efficiently as protein 
expression and showed that the separation by principal component analysis (PCA) is similar. 
Moreover, iPSCs and ESCs were almost indistinguishable from each other on the PCA 
confirming our model. Strikingly, iPSCs and ESCs were separated on one side of the PCA, 
with hFF and RKO on the other side and EBs in an intermediate position in both stability and 
expression demonstrating that both parameters can separate various degrees of stemness. 
Indeed, EBs consist of a group of differentiated, progenitor stem and pluripotent cells so they 
still retain in part features of their parental iPSCs (Figures 21a and b). Additionally, the log 
scaled stability (Sm) and expression (Exp) FC of each cell line against iPSCs did not 
correlate, demonstrating that the two measurements are independent (Figure 21c).  
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4.5.2 ProteoTracker interface visualizes protein trajectories in stability and 
expression between cell types. 
This prompted us to design a visualization approach to simultaneously study protein thermals 
stability and expression changes associated with the transition from one cell type to another. 
We used a mock transition following a pluripotency scale starting with iPSCs as our initial 
point then to EBs and finally hFF as terminally differentiated cells. What we wanted to see is 
whether we could distinguish general features of differentiated cells compared to pluripotent 
cells. However, observing this many proteins simultaneously (7778) on two dimensions 
(stability and expression) and another pseudo-time dimension, proved to be difficult. So, we 
opted to split the 2-dimensional plots into 5 sectors according to their log2 scaled protein 
thermal stability FC and expression FC for EBs versus iPSCs and hFF versus EBs (Figure 
21d). The 5 sectors corresponded to proteins that are stabilized and upregulated (A), 
stabilized and downregulated (B), destabilized and downregulated (C), and destabilized and 
upregulated (D) (Figure 22). To assign proteins in their respective quadrant, a combined 
Fisher score was calculated if proteins passed the test (combined p-value <0.05) they were 
placed in the sector corresponding to their stability and expression FC sign, otherwise they 
were assigned to sector E thus comprising proteins that are not significantly changing. 
Finally, we used Sankey diagrams to monitor the transition of each protein from one sector to 
another following the transitions from one cell type to another, resulting in the ProteoTracker 
web interface (http://www.proteotracker.genexplain.com/) (Figure 22).  
Figure 21. Protein thermal stability and expression changes between cell types. (a) and (b) PCA of 
normalized stability and expression measurements in hFF, RKO, iPSC, EB, and ESC. (c) Number of proteins 
with FC > 3*standard deviation and Pearson correlation of Sm and Exp FC. (d) Protein trajectories in cell type 
transitions were defined as positions in a 2D plot of log2 FCs for Sm and Exp compared to the original type. 
Transition (T1) was from pluripotency (iPSC) to early differentiation (EB), and (T2) from EB to terminal 
differentiation (hFF).  
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Figure 22. Sankey diagram maps protein trajectories during proteome transitions. Sankey diagram based 
on assigning to a significant sector (A - D) a protein trajectory in (T1) and (T2) (Figure 21d) when the combined 
p-value for changes in stability and expression was <0.05, and to an insignificant sector E otherwise. Each
protein trajectory transition group (PTTG) of proteins undergoing a transition from a sector X in (T1) to a sector
Y in (T2) (25 PTTGs in total) was submitted to a Gene Ontology (GO) enrichment analysis with all quantified
proteins as background. For each sector in PTTG, the density distribution of the distances on the 2D plot in (T1)
and (T2) is plotted and the percentage of proteins transiting from any sector in T1 to sector Y is calculated, and
their number is given.
4.5.3 PSCs have lower amounts of mature ribosomes than differentiated 
cells. 
We performed pathways enrichment on the various proteome trajectories that we termed 
proteome trajectory transition group (PTTG) to design the transition of a protein group from 
sector to sector. Strikingly PTTG from B to A contained most ribosomal proteins (Figures 
22e and 23a). We observed no differences in ribosomal protein stability or expression 
between iPSCs and ESCs (Figure 23 b). However, ribosomal proteins were stabilized in all 
differentiated cells compared to iPSCs and significantly changed in expression only in EBs 
(Figures 23 c, d, and e). Since almost all ribosomal proteins showed the same trend, we 
hypothesized that it stems from a difference in the number of assembled ribosomes which 
would explain the increased stability in differentiated cells. We studied ribosome density 
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profiles between RKO and iPSC which have a close dividing rate since it can influence the 
profile. RKO showed much more assembled ribosomes. Additionally, iPSCs had the lowest 
translation rate compared to hFF and RKO.  
Figure 23. Ribosomal proteins are stabilized in differentiated cells. (a) Sankey diagram highlighting the 
movements of ribosomal proteins between the EB/iPSC to hFF/EB transition. (b), (c), (d), and (e) Two-
dimensional plots of Sm and Exp FC of ESC, EB, hFF, and RKO against iPSC.  
4.5.4 Proteins involved in late steps of ribosome maturation are 
downregulated in iPSCs compared to differentiated cells. 
Since we found a difference in the quantity of assembled ribosomes leading to a higher 
translation rate in differentiated cells, we asked whether this could come from a defect within 
the ribosome assembly line. We studied ribosomal maturation factors expression in several 
cell lines against iPSCs including hFF, EBs, neurons differentiated from our iPSCs, RKO and 
HT29. Strikingly, we only see 11 factors that were downregulated on average in iPSCs 
compared to all the cell lines and the most downregulated is SBDS which ejects EIF6 with 
the help of the GTPase EFL1 from the 60S subunit as a late step of ribosome assembly, 
leading to association with 40s and translationally competent ribosomes (Finch et al., 2011; 
Menne et al., 2007; Weis et al., 2015) (Figure 24a). Incidentally, both EFL1 and EIF6 were 
among the 11 downregulated factors (Figure 24a). However, SBDS is the only ribosome 
maturation factor that was downregulated in every cell line in comparison to iPSCs (Figure 
24b). Paradoxically, iPSCs had higher levels of ribosomal proteins’ expression than other cell 
lines. Then, constitutive repression of SBDS expression could be a mechanism used by PSCs 
to maintain a lower pool of translationally competent ribosomes while maintaining assembled 
subunits as we see in the ribosome density profile (slightly higher level of 40S and a higher 
level of 60S).  
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Figure 24. Expression of ribosome maturation factors. (a) Mean expression FC of ribosome maturation 
factors in iPSC against EB, hFF, HT29, Neurons, and RKO and scheme of the late step of ribosome maturation. 
(b) Expression FC of the 11 most downregulated ribosome maturation factors in iPSC against each other cell
lines. Error bars represent the standard deviation of the mean, n=3.
4.5.5 SBDS knock-down slows down differentiation of iPSCs. 
Finally, we investigated the effect of SBDS inhibition on cellular differentiation, our 
objective was to show that repressing SBDS expression slows down differentiation of iPSCs 
since they would need higher levels of SBDS and functional ribosomes to differentiate 
properly. Thus, we differentiated iPSCs into embryoid bodies for three days and then plated 
them to trigger random differentiation for three more days before treatments with siRNA for 
three days. We then measured protein expression and mRNA levels. SBDS expression level 
had an opposite behavior to pluripotency markers OCT4 and NANOG as well as compared to 
the average expression of ribosome maturation factors and ribosomal proteins highlighting 
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that SBDS level anticorrelates with pluripotency markers and other proteins from the same 
pathway. SBDS KD leads to downregulation of proteins involved in developmental pathways 
suggesting that it slowed down differentiation. To further confirm this observation and study 
the effect of SBDS KD in another system, we plated our iPSCs onto Matrigel instead of 
laminin 521. Matrigel is known to allow more spontaneous differentiation than culture on 
laminin (Rodin et al., 2014), and our cells were not adapted to the system so they 
spontaneously differentiated even more. We measured mRNA expression of SBDS, OCT4, 
NANOG, and of several lineage-specific markers GATA4, SOX17, PAX6, and SOX7. SBDS 
KD leads to a significant increase in mRNA levels of OCT4 and a decrease of all the markers 
apart from GATA4 which did not change (Figure 25). Collectively, our data showed that 
SBDS KD can be used for slowing down differentiation and potentially help maintain PSCs 
in vitro culture. 
Figure 25. SBDS siRNA knock-
down in iPSCs plated on Matrigel. 
Ratios of mRNA levels of 
pluripotency markers and several 
lineage-specific markers as well as 
SBDS measured by qRT-PCR 
against the scrambled siRNA 
control. Error bars represent the 
standard deviation of the mean, n=3.  
Conclusions 
Here we further develop PISA analysis by adding an expression-based correction to the 
stability measurement. This correction is important for samples that potentially have a 
difference in protein expression, otherwise, the readout of the PISA assay would be an 
amalgam of stability and expression changes. The other advantage is that the expression 
measurement can be used as a standalone measurement and this idea was the basis of the 
PISA-Express methodology presented here. In addition to PISA-Express, we also developed 
an online visualization and analysis tool, ProteoTracker, that can be used to explore our and 
own, uploaded data for analysis. Any proteomics dataset containing two-dimensional 
measurements along a third dimension like time for instance can be analyzed through our 
interface offering new possibilities for the proteomics community. Here we also demonstrate 
for the first time that a combination of protein stability and expression measurement in a 
purely biological context can lead to biomarker discovery by highlighting SBDS as a key 
controller of translation in PSCs. SBDS KD could be used as a tool to culture iPSCs in vitro. 
Moreover, since several types of tissue-resident stem cells also exhibit low translation rates it 
could come in handy to adapt them to in vitro culture, this warrants further investigation.  
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
Proteomics is a fast-evolving field that has been more and more used and trusted in biology 
and medical sciences in recent years. When the work presented in this thesis started, the 
emphasis in the proteomics field was mainly on analytical depth. How many proteins can we 
identify with a theoretically illimited amount of sample material (Bekker-Jensen et al., 2017)? 
Initially, the classical experiment was label-free (Hornburg et al., 2014; Nagaraj et al., 2012; 
Pirmoradian et al., 2013), and this was mainly replaced by multiplexing strategies to quantify 
more proteins (McAlister et al., 2014; Zhou et al., 2013). Indeed, sample multiplexing did not 
necessarily reduce the instrumental time because off-line fractionation was employed to reach 
high numbers of quantified proteins. This is reflected in the low number of proteins identified 
in the first label-free analysis of paper I with 2116 proteins common in all samples, while 
8898 proteins common in all samples were quantified in the second multiplexed analysis with 
similar analysis time. The field was already investigating features that are only available in 
proteomics such as studies of protein PTMs or protein synthesis/degradation. However, the 
focus shifted, even more, when protein numbers attained in one analysis were sufficient for 
the field to stand its ground against transcriptomics analysis (Bekker-Jensen et al., 2017). 
Analytical depth is now a problem more akin to single-cell proteomics, where proteomics 
once again tried to catch up in the race against transcriptomics. Reduced instrumental time 
and higher throughput of mass spectrometry analysis are underway and have seen 
tremendous improvements (Bian et al., 2020; Messner et al., 2021; Meyer et al., 2020). For 
the rest of the proteomics field, a large portion of the research attention is now on: 
- reduced sample amount.
- development of complementary unbiased approaches to protein expression
measurements.
- analysis and visualization of datasets of ever-increasing complexity.
These technical hurdles are particularly relevant in biology where accurate and alternative 
parameters measurements of protein properties are crucial to properly interpret molecular 
mechanisms or explain observed phenotypes. In addition, the most challenging and 
interesting biological materials are rarely available in large amounts. Finally, studies 
involving a larger and larger number of samples such as databases and atlases are becoming a 
routine in proteomics (Cho et al., 2021; Jarzab et al., 2020; H. J. Johansson et al., 2019; 
Mateus et al., 2020; Nusinow et al., 2020; D. Wang et al., 2019) and we have also added our 
contribution (Saei et al., 2019). In this thesis we introduce methods and experimental 
strategies that contribute to overcoming some of these challenges.  
First, PISA developed in paper II paves the way for higher throughput studies of protein 
thermal stability and protein solubility measurements in general. PISA also requires less 
sample material than TPP. Using PISA in paper IV instead of TPP allowed us to analyze the 
three drugs and vehicle control in duplicates in one set and obtain data for four replicates of 
the three experiments in six TMT sets corresponding to 60 TMT sets in a classical 1D-TPP 
analysis involving 10 temperature points per samples. This is also relevant in paper V, where 
we could monitor simultaneously protein expression and thermals stability in five cell types 
in one TMT10 set per replicate. Even though we used less material and reduced the 
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instrumental time that we would need in a classical TPP analysis, we did not use small 
sample amounts per se, and this should be addressed in future studies. 
Next, we combined the methodologies that we developed and existing methods to elucidate 
drug MOA and to study cellular dynamics (papers I, III, IV, and V). In paper I, we showed 
that the naturally occurring cell variations in in vitro cell culture over time are on par with 
those of cells treated with anticancer compounds at IC50. These results stress the use of time-
matched controls and highlight the high plasticity and dynamics of the cellular proteome even 
in a stable environment that is in vitro cell culture. In papers III and IV we studied the target 
landscapes and MOA of several redox-regulating anti-cancer compounds using a 
combination of chemical proteomics approaches namely FITExP, TPP/PISA, and redox 
proteomics. We demonstrate that one method is not enough for accurately deconvoluting 
MOA of AF but considering the complementarity and overlap between the three methods we 
could pinpoint the target TXNRD1. We also demonstrate that disulfide bond formation or 
reduction can lead to alteration of proteome thermal stability by directly comparing TPP and 
redox proteomics readouts which were later confirmed using the newly developed SIESTA 
(Saei et al., 2021). Lastly, in paper IV we highlight the usefulness of analyzing the effect of 
multiple drugs having a target in common, on the proteome. This helped us to establish the 
specificity of each of the compounds toward their common target and deconvolute effects 
that are due to the inhibition of the common target from other effects. This study serves as an 
example of combining attributes of chemical proteomics methods and of the compounds 
themselves and could be used as a model for evaluating compounds that are structural or 
functional analogs in drug development.  
Going one step further, after demonstrating that protein stability and expression 
measurements (or FITExP analysis) are orthogonal (papers II, III, and V) we decided to 
merge the two dimensions or facets in one analysis resulting in PISA-Express. One of the 
disadvantages of the current visualization and analysis tools available in multifaceted 
proteomics is that they tend to compress information (McInnes et al., 2018; Van Der Maaten 
& Hinton, 2008). Visualizing the behavior of all proteins in two parameters without reduction 
of the information is easy but extracting the evolution of these parameters along a third 
parameter like pseudo-time or even a three ways comparison is not trivial. Here, we were 
interested in monitoring both stability and expression simultaneously for all proteins and 
particularly the changes of protein properties in both parameters for comparing several 
successive conditions (cell types in our case). ProteoTracker allows visualizing if a protein or 
group of proteins have significantly altered thermal stability and expression in one cell type 
compared to another and tracks their behavior during successive cell type transitions. These 
characteristics are rather unique in proteomics. In summary, ProteoTracker represents our 
attempt to overcome some challenges in data visualization and analysis and should be 
improved in the future to include additional analyses. We also used a pseudo-cell transition 
where we studied cell lines that were static apart from differentiating EBs, even though they 
were reprogrammed and then differentiated from the same parental line. Monitoring 
differentiation of more defined cell lineages at various steps of differentiation should 
showcase the utility of the interface more than in the current study and should also be 
investigated in the future.  
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Finally, the work presented here displays analyses that are unique to the proteomics world 
(papers II, III, IV, and V). Protein expression levels can be estimated through 
measurements of mRNA levels. However, protein and mRNA levels do not always correlate 
perfectly due to post-transcriptional events (Yansheng Liu et al., 2016). This is particularly 
true when the cell undergoes strong phenotypic alterations such as in differentiation, division, 
stress response such as in response to chemical treatment (Cheng et al., 2016; Fournier et al., 
2010; Jayapal et al., 2008; Kristensen et al., 2013; M. V. Lee et al., 2011; Maier et al., 2011; 
Vogel et al., 2011), as in papers I, II, III, IV, and V. Furthermore, only proteomics allows 
one to study post-translational events such as PTM, PPI, protein degradation and so on. 
Measurement of protein thermal stability is a powerful tool for observing multiple protein 
properties simultaneously. Indeed, TPP can measure changes in protein physico-chemical 
properties and so far, it was shown that TPP can detect ligand binding, PPI, and PTM. All 
these parameters can be theoretically monitored at once, the difficulty is then to find out the 
cause of protein stability alterations when using TPP in a biological system. In paper V we 
deconvolute and explain the difference in stability of ribosomes between PSCs and 
differentiated cells. We also link thermal stability alterations of histones and proteins 
involved in glycolysis and oxidative phosphorylation to differences in cell metabolism and 
chromatin compaction. Control of translation through modulation of ribosome biogenesis is 
an example of post-transcriptional control and altered stability of ribosomes could not be 
highlighted other than with proteomics analysis. Therefore, efforts on developing methods 
that are unique to the field and provide complementary information to already existing 
measurements are valuable to biologists (papers II and V). Particularly, in paper V we 
further set the stage for using protein thermal stability as an alternate measurement to protein 
expression to elucidate molecular mechanisms in biological studies. This was already 
initiated by the work of Becher et al. and Dai et al. by studying the different phases of the cell 
cycle using TPP/MS-CETSA (Becher et al., 2018; Dai et al., 2018). However, now that the 
utility of TPP/PISA in cell biology has been established using relatively accessible cellular 
systems, more challenging systems should be investigated in future work. More defined and 
rare cell types are described by cell biologists where the differences in protein expression are 
minimal or almost absent from one cell type to another and could often be missed by 
conventional analysis. Adding protein thermal stability measurements to expression 
measurements can greatly increase the value and discovery potential in such studies and 
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